Financial Performance - Fourth quarter 2025 revenues reached $27.0 million, a 72% increase compared to $15.6 million in Q4 2024[6] - Fee revenue for the fourth quarter was $22.9 million, a 67% increase year-over-year[5] - Adjusted EBITDA for Q4 2025 was $3.3 million, up 248% from $0.9 million in Q4 2024[7] - Full-year 2025 revenues totaled $75.6 million, a 2% increase from $74.2 million in 2024[8] - The company reported a net loss of $1.9 million for the year, an improvement from a net loss of $4.1 million in 2024[9] - Operating revenues for Q4 2025 were $26,950,000, a 72% increase from $15,637,000 in Q4 2024[21] - Net income for the year ended December 31, 2025, was a loss of $1,941,000, an improvement from a loss of $4,119,000 in 2024[23] - Total operating revenues for the year ended December 31, 2025, reached $75,625, compared to $74,154 in 2024, reflecting a growth of 1.98%[27] - The net loss for the year ended December 31, 2025, was $(1,941), a slight improvement from $(4,119) in 2024[24] Cash Flow and Assets - Operating cash flow generated in 2025 was $14.0 million, with free cash flow of $7.2 million[5] - Cash and cash equivalents increased significantly to $4,907,000 in 2025 from $1,385,000 in 2024[22] - Free cash flow for the year was $7,244,000, a turnaround from a negative free cash flow of $2,601,000 in 2024[23] - The company reported a net cash provided by operating activities of $7,694 for the year ended December 31, 2025, compared to a net cash used of $(1,866) in 2024[25] Expenses and Liabilities - General and administrative expenses were reduced by 9% year-over-year, aided by the implementation of AI software[3] - The total operating expenses for the year ended December 31, 2025, were $77,289, compared to $78,703 in 2024, indicating a decrease of 1.8%[27] - Total liabilities increased to $40,202,000 in 2025 from $13,589,000 in 2024, indicating a significant rise in financial obligations[22] Strategic Initiatives - The company expanded its customer base to include unconventional exploration sectors such as carbon capture and geothermal[4] - A capital budget of $3 million was approved for 2026, including a final payment of $0.9 million for single node channels[12] - Discussions with controlling stockholder Wilks Brothers, LLC may lead to potential transactions involving asset contributions or sales[17] Other Financial Metrics - The accumulated deficit at the end of 2025 was $139,560,000, slightly worsening from $137,619,000 in 2024[22] - The company reported a basic income per share of $0.02 for Q4 2025, compared to a loss of $0.03 per share in Q4 2024[21] - Total current assets rose to $21,835,000 in 2025, compared to $14,541,000 in 2024, reflecting a 50% increase[22] - Total assets grew to $56,010,000 in 2025, up from $30,870,000 in 2024, marking an 81% increase[22] - Adjusted EBITDA for the year ended December 31, 2025, was $4,682, an increase from $1,961 in 2024[25] - EBITDA for the year ended December 31, 2025, was $4,154, compared to $1,475 in 2024, showing significant growth[25] - The company incurred strategic transaction costs of $528 for the year ended December 31, 2025, consistent with the previous year[25] - For the three months ended December 31, 2025, the consolidated net income was $569, compared to a net loss of $802 for the same period in 2024[24] - Fee revenue for the three months ended December 31, 2025, was $13,752, up from $15,637 in the same period of 2024[27] - The company reported a decrease in general and administrative expenses to $9,010 for the year ended December 31, 2025, from $9,946 in 2024[27]

Financial Performance - DiaMedica reported a net loss of $32.8 million for the year ended December 31, 2025, compared to a net loss of $24.4 million in 2024, representing a 34.5% increase in losses year-over-year[15]. - DiaMedica's comprehensive loss for 2025 was $32.7 million, compared to a comprehensive loss of $24.4 million in 2024, indicating a 33.9% increase in overall losses[15]. - Net loss for the year ended December 31, 2025, was $32,766, compared to a net loss of $24,444 in 2024, representing a 33.5% increase in losses[19]. Expenses - Research and Development (R&D) expenses increased to $24.6 million in 2025 from $19.1 million in 2024, reflecting a 28.9% rise due to ongoing clinical trials and global expansion efforts[15]. - General and Administrative (G&A) expenses rose to $9.8 million in 2025, up from $7.6 million in 2024, marking a 29.1% increase attributed to higher personnel and investor relations costs[9]. - Share-based compensation increased to $3,846 in 2025 from $2,085 in 2024, reflecting an increase of 84.5%[19]. Cash and Liquidity - Cash and cash equivalents increased to $15.6 million as of December 31, 2025, compared to $3.0 million in 2024, indicating a significant improvement in liquidity[17]. - Cash and cash equivalents at the end of the period increased to $15,647 in 2025 from $3,025 in 2024, indicating a significant improvement in liquidity[19]. - DiaMedica has a cash runway expected to fund operations through the second half of 2027, with $60 million in cash, cash equivalents, and investments as of the reporting date[5]. Assets and Financing - Total assets grew to $61.4 million in 2025, up from $46.3 million in 2024, reflecting a 32.5% increase driven by higher cash reserves and marketable securities[17]. - Proceeds from the issuance of common shares, net of offering costs, rose to $43,282 in 2025, compared to $11,747 in 2024, marking a 267.5% increase[19]. - Net cash provided by financing activities was $43,876 in 2025, up from $11,994 in 2024, showing a substantial growth of 265.5%[19]. Operational Updates - The company anticipates completing the interim analysis for the ReMEDy2 trial in the second half of 2026, with enrollment approaching 70% of the required participants[3]. - The company received regulatory approval from Health Canada to initiate a Phase 2 study of DM199 in early-onset preeclampsia, with enrollment expected to complete in the first half of 2026[5]. Changes in Financial Position - Net cash used in operating activities increased to $29,062 in 2025 from $22,076 in 2024, reflecting a 31.7% rise[19]. - The company reported a net cash used in investing activities of $2,192 in 2025, compared to a net cash provided of $8,564 in 2024, indicating a shift in investment strategy[19]. - The company experienced a significant change in accounts payable, increasing to $535 in 2025 from $14 in 2024[19]. - The company reported a decrease in prepaid expenses and other assets by $254 in 2025, contrasting with an increase of $184 in 2024[19].

Financial Performance - Rezolve incurred a net loss of $101.4 million in the year ended December 31, 2025, and $173.5 million in the year ended December 31, 2024, resulting in a total shareholders' deficit of $246.8 million as of December 31, 2025[19]. - Rezolve had an accumulated deficit of $359.6 million and incurred a net loss of $101.4 million for the year ended December 31, 2025[39]. - Cash and cash equivalents totaled $111.1 million as of December 31, 2025, an increase of $101.4 million from December 31, 2024[39]. - The company faces a working capital deficit of $87.1 million as of December 31, 2025[39]. - Rezolve recorded a $63.3 million impairment charge related to its holdings of SQD tokens for the year ended December 31, 2025[52]. Revenue Generation - Rezolve expects to generate revenues primarily through subscription fees and one-time transaction fees, relying on partnerships with companies like Microsoft, Google, and ACI, which are currently pre-revenue[18]. - Rezolve's subscription model may limit its ability to rapidly increase total revenues, as revenues from new customers are recognized over the subscription term[43]. - The company raised $520.7 million during 2025 and into 2026 to support its operations[41]. Market and Economic Conditions - Rezolve's performance is subject to global economic conditions, which may adversely affect spending by small and medium-sized businesses (SMBs) and technology investments[20]. - Economic downturns may lead to reduced retail sales, potentially causing merchants using Rezolve's platform to cease operations or reduce spending[24]. - The markets for Rezolve's offerings are new and evolving, making it difficult to predict customer adoption and demand for its platform[31]. Competition and Risks - The company faces risks related to competition in the SaaS market, including the introduction of competing platforms and pricing strategies[21]. - Rezolve faces significant competition from established companies with larger customer bases and more resources, which may impact its ability to compete effectively[56]. - The company may encounter increased operational costs and risks related to compliance with payment processing regulations, which could adversely affect its financial condition[58]. - Rezolve's business model is susceptible to risks associated with international sales, including compliance with various foreign laws and regulations[44]. Operational Challenges - The company plans to increase its investment in sales and marketing, research and development, and technical infrastructure to support growth, which may hinder its ability to achieve profitability in the near term[19]. - Rezolve's sales cycle is lengthy, making it difficult to predict revenue generation from new clients, which could hinder revenue growth rates[68]. - Rezolve's platform must meet service-level commitments to avoid revenue loss and reputational damage, highlighting the importance of operational reliability[69]. Technology and Development - Rezolve has developed its own proprietary LLM, brainpowa, but also relies on third-party AI technologies, which may affect its operational capabilities if access or pricing changes[28]. - The company is actively developing its AI technologies, including the proprietary brainpowa LLM, which is integral to its Brain Commerce suite[118]. - Rezolve anticipates increased investment in AI technologies to enhance product offerings, although there are inherent risks in developing and deploying these technologies[118]. Compliance and Regulatory Issues - The political and regulatory framework for AI technology is evolving, which may increase operating expenses and affect Rezolve's business[48]. - The EU AI Act, effective August 2024, may impose stringent compliance requirements on Rezolve, affecting its operations in the EU market[94]. - The company must navigate complex legal and regulatory compliance related to anti-corruption and anti-bribery laws, which could impact its financial condition and reputation[129]. Intellectual Property and Legal Risks - Rezolve faces risks related to intellectual property infringement claims, which could result in substantial expenses and disrupt business operations[112]. - The company may be required to modify its practices or pay substantial damages in the event of intellectual property claims, impacting its financial results[113]. - Rezolve's reliance on open-source software may expose the company to litigation risks and significant legal expenses, potentially disrupting its business operations[114]. Human Resources and Management - Rezolve's future success is dependent on attracting and retaining skilled personnel, particularly in technical and engineering roles, amid intense competition for talent[75]. - The loss of key management personnel could significantly disrupt Rezolve's operations and delay the achievement of strategic objectives[76]. Shareholder and Market Considerations - The company does not intend to pay dividends for the foreseeable future, focusing instead on retaining earnings for operations and expansion[70]. - Rezolve's status as an "emerging growth company" allows it to rely on reduced disclosure requirements, which may make its shares less attractive to investors[144]. - The trading price of Rezolve's Ordinary Shares is likely to be volatile, influenced by various external factors beyond the company's control[137]. Currency and Economic Factors - Rezolve's revenue for the year ended December 31, 2025, was denominated in multiple currencies, including USD, EUR, GBP, AUD, CHF, PLN, SGD, and INR, indicating a diverse revenue stream[455]. - A 10% appreciation or depreciation in foreign currencies against the US dollar could have increased or decreased the company's revenue for the year ended December 31, 2025, by significant amounts, including $1,913,635 for GBP and $323,875 for EUR[458]. - The company has limited interest rate risk as its convertible debt and promissory notes are non-interest bearing, with short-term debt linked to SOFR[454].

Revenue Performance - Total revenue for the year ended December 31, 2025, was $285.9 million, a slight decrease of $142, or less than 1%, compared to $286.1 million in 2024[197]. - Revenue from IoT Connectivity services decreased by approximately $2.9 million, or 1%, to $224.0 million in 2025, primarily due to transitioning operations in Connectivity Enablement-as-a-Service (CEaaS)[199]. - Revenue from IoT Solutions increased by approximately $2.7 million, or 5%, to $62.0 million in 2025, driven by additional volume from key customers[200]. - Total revenue from IoT Connectivity was $224.0 million in 2025, slightly down from $226.9 million in 2024, with a gross margin of 39.5%[228]. - IoT Solutions revenue increased to $61.9 million in 2025 from $59.2 million in 2024, with a gross margin improvement to 32.1%[229]. Cost and Expenses - Cost of revenue for the year ended December 31, 2025, was $128.0 million, an increase of $1.9 million, or 1%, compared to $126.2 million in 2024[202]. - Selling, general, and administrative (SG&A) expenses decreased by approximately $24.5 million, or 17%, to $115.5 million in 2025, primarily due to restructuring events and reduced compensation-related expenses[205]. - Other (income) expense, net decreased by $6.0 million to $(4.2) million in 2025, representing a year-over-year decrease of 324%[209]. - Integration-related restructuring costs for 2025 were primarily related to severance and office lease terminations, totaling $19.8 million[219]. Profitability and Cash Flow - EBITDA for 2025 was $43.1 million, compared to $(44.4) million in 2024, indicating a significant improvement[219]. - Adjusted EBITDA increased to $63.3 million in 2025 from $53.1 million in 2024, reflecting a positive trend in operational performance[219]. - Free cash flow improved to $8.9 million in 2025 from $(3.5) million in 2024, indicating better liquidity[222]. - Non-GAAP Profit for 2025 was $159.3 million, down from $161.1 million in 2024, with a Non-GAAP Margin of 55.7%[228]. Tax and Goodwill - The company recorded an income tax recovery of $3.6 million for the year ended December 31, 2025, due to the impact of the One Big Beautiful Bill Act (OBBBA)[187]. - Income tax benefit decreased by approximately $4.4 million to $(1.6) million in 2025, with an effective tax rate decrease of 2% to 2.4%[214]. - Goodwill impairment was $0 for the year ended December 31, 2025, compared to $65.9 million in 2024, marking a year-over-year decrease of 100%[207]. - The company completed its annual goodwill impairment test on October 1, 2025, and determined there was no goodwill impairment[274]. Debt and Liquidity - Total long-term debt as of December 31, 2025, was approximately $295.2 million, slightly down from $295.7 million in 2024[244]. - Cash on hand as of December 31, 2025, was approximately $26.7 million, with an additional $25.0 million available on the Revolving Credit Facility[242]. - The accrued and unpaid dividends on Series A-1 Preferred Stock as of December 31, 2025, amounted to $47.9 million, compared to $23.8 million in 2024, showing an increase of approximately 101.68%[260]. - The Total Net Leverage Ratio is set to decrease to 5.25:1.00 for periods ended December 31, 2025, and thereafter, down from 6.25:1.00 for earlier periods[249]. - The Company was in compliance with all financial covenants as of December 31, 2025, for both the Credit Facilities and Backstop Notes[250][255]. Operational Metrics - Total Number of Connections increased to 20.9 million as of December 31, 2025, up from 19.7 million in 2024, representing a growth of approximately 6.09%[233]. - Average Connections Count for the year ended December 31, 2025, was 20.3 million, compared to 18.7 million in 2024, indicating a year-over-year increase of about 8.55%[233]. - Estimated Annual Recurring Revenue (eARR) from the sales funnel was approximately $87 million as of December 31, 2025[235]. - Average Revenue per User (ARPU) decreased to $0.93 for the three months ended December 31, 2025, down from $0.97 in 2024, reflecting a decline of about 4.12%[239]. Mergers and Acquisitions - The company entered into a merger agreement on February 26, 2026, with KONA Parent, with each share of common stock to be converted into cash of $9.25 per share[188]. - The closing of the merger transaction is expected during the second or third quarter of 2026, subject to various approvals[193]. Cash Flow Activities - Cash provided by operating activities for the year ended December 31, 2025, increased to $18,487,000 from $9,123,000 in 2024, primarily due to a lower net loss and changes in non-cash adjustments[263][264]. - Cash used in investing activities decreased to $9,590,000 in 2025 from $12,672,000 in 2024, mainly due to lower additions to intangible assets[263][265]. - Cash used in financing activities decreased to $2,068,000 in 2025 from $3,782,000 in 2024, primarily due to reduced share repurchases and lower payments of employee tax withholding related to equity awards[263][266]. Other Considerations - The Company deferred payment of preferred dividends on Series A-1 preferred stock in both 2025 and 2024, as permitted under the terms of the shares[240]. - The company had a total of $71.1 million in purchase commitments payable that were not recorded as liabilities on the consolidated balance sheet as of December 31, 2025[267]. - The company’s revenue is primarily derived from IoT Connectivity and IoT Solutions, recognized under ASC 606[284][285]. - The company had significant judgments and estimates regarding income taxes, which could materially impact financial statements[279][280].

Financial Performance - Revenue for Q4 2025 was $73.9 million, roughly flat compared to the same period last year, while Total Connections increased to 20.9 million, up 6% from 19.7 million[4] - Net Loss for Q4 2025 decreased to $18.5 million, an improvement of $7.0 million or 27% from the same period last year[4] - Adjusted EBITDA for Q4 2025 increased to $17.7 million, up $3.7 million or 26% from the same period last year[4] - Full year revenue totaled $285.9 million, compared to $286.1 million one year ago[4] - Net Loss for the full year was $63.0 million, an improvement of $83.1 million or 57% from $146.1 million one year ago[4] - Adjusted EBITDA for the full year was $63.3 million, an increase of $10.2 million or 19% from the previous year[4] Cash Flow and Expenditures - Free Cash Flow for the full year was $8.9 million, an improvement of $12.4 million year over year[4] - Net cash provided by operating activities for Q4 2025 was $10,449,000, compared to $2,057,000 in Q4 2024, representing a significant increase[22] - Free Cash Flow for Q4 2025 reached $7,844,000, up from $1,562,000 in Q4 2024[22] - For the twelve months ended December 31, 2025, net cash provided by operating activities was $18,487,000, compared to $9,123,000 in 2024, indicating strong operational performance[22] - The company achieved a Free Cash Flow of $8,897,000 for the full year 2025, a turnaround from a negative Free Cash Flow of $(3,549,000) in 2024[22] - Total capital expenditures for the twelve months ended December 31, 2025 were $9,590,000, down from $12,672,000 in 2024[22] Business Developments - The company entered into a Merger Agreement with KONA Parent, L.P. for an all-cash transaction with an enterprise value of approximately $726 million[6] - Total Connections for the full year remained at 20.9 million, consistent with the end of Q4 2025[5] - IoT Connectivity revenue for Q4 2025 was $57.2 million, representing 78% of total revenue[5]

Financial Performance - Nakamoto reported a total revenue of $444,924 for Q4 2025, a decrease from $603,887 in Q4 2024[9] - For the year ended December 31, 2025, total revenue was $1.82 billion, a decrease from $2.72 billion in 2024[15] - Revenue for Q4 2025 was $444.9 million, a decrease of 26.4% compared to $603.9 million in Q4 2024[27] - The net income for Q4 2025 was $37.3 million, compared to a net loss of $1.0 million in Q4 2024[27] - The company reported a basic net income per share of $0.07 for Q4 2025, compared to a loss of $0.17 per share in Q4 2024[27] - The company reported a total non-operating income of $198.0 million for Q4 2025, compared to $21.1 million in Q4 2024[27] Operating Expenses and Losses - Operating expenses for Q4 2025 totaled $161.2 million, compared to $1.6 million in Q4 2024, primarily driven by compensation and administrative costs[9] - Total operating expenses for Q4 2025 were $161.2 million, significantly higher than $1.6 million in Q4 2024, primarily due to a loss on change in fair value of digital assets of $142.6 million[27] - The adjusted operating loss (non-GAAP) for Q4 2025 was $5.2 million, reflecting a significant increase in operational focus on Bitcoin-related activities[9] - Adjusted operating loss (non-GAAP) for the year was $(13.6) million, excluding certain expenses[25] - Operating loss for the year ended December 31, 2025 was $197.1 million, compared to a loss of $3.3 million for the year ended December 31, 2024[27] Digital Assets and Investments - The company experienced a loss on changes in the fair value of digital assets amounting to $142.6 million, reflecting a decline in Bitcoin value from $114,078 to $87,519[10] - The loss on changes in fair value of digital assets was $166.2 million, reflecting a decline in Bitcoin value from an average purchase price of $118,171 to $87,519[16] - The company incurred a loss on investments of $10.8 million in Q4 2025, while there were no such losses reported in Q4 2024[27] - Nakamoto continues to view its Bitcoin holdings as a long-term strategic treasury asset, separating long-term exposure from short-term liquidity needs[20] Strategic Initiatives and Acquisitions - The company initiated an exit from its legacy Healthcare Operations, which is expected to reduce operating losses and streamline its cost structure[11] - Nakamoto completed the acquisitions of BTC Inc and UTXO Management in February 2026, enhancing its media, asset management, and advisory capabilities[6] - The company aims to reinvest operating cash flow into growth initiatives and Bitcoin accumulation, enhancing capital allocation flexibility[6] - Nakamoto's strategic transformation includes a focus on building a scalable Bitcoin-native operating business with diversified revenue streams[5] - Management expects improved operating performance as the integration of new subsidiaries progresses and the cost structure is streamlined[8] - The company plans to expand its market presence and explore new product development opportunities in the upcoming fiscal year[27] Shareholder Information - As of March 27, 2026, shares outstanding increased to 690,018,254, with fully diluted shares at 892,723,518[21] - Fully diluted shares outstanding increased to 526.1 million as of December 31, 2025, from 511.6 million in the previous quarter[28] - As of December 31, 2025, the company's enterprise value was $341 million, with a market capitalization of $154 million and notes payable of $210 million[21] Transaction-Related Costs - Transaction-related expenses amounted to $5.0 million, primarily due to costs associated with the Nakamoto merger[18] - Operating losses in healthcare operations were driven by decreased cash-pay patient services and the closure of one clinic[18]

Macroeconomic Factors - The company is significantly affected by macroeconomic factors such as inflation, tariffs, and supply chain disruptions, which could negatively impact sales and profitability [56]. - Over half of the goods sold by the company originate from China, making it particularly vulnerable to changes in U.S. trade policy and tariffs [57]. - Consumer spending is influenced by various external factors, including rising costs of living and consumer confidence, which could affect demand for merchandise [58]. - The company faces risks associated with importing merchandise, including increased tariffs and supply chain disruptions due to geopolitical conflicts [81]. Competition and Market Dynamics - The retail industry is highly competitive, with increasing pressures from both traditional and online retailers, which could impact the company's market share [60]. - The company must effectively advertise and market its business to drive customer traffic, as competitors may have more resources for marketing [70]. Operational Challenges - The company faces challenges in effectively managing inventory levels, which could lead to excess inventory and markdowns, adversely affecting profit margins [72]. - Labor shortages and increased turnover rates could negatively impact the company's ability to execute its retail strategies and manage costs [66]. - Disruptions in the supply chain or information systems could adversely affect the company's ability to process sales and deliver products in a timely manner [77]. Technology and Cybersecurity - Cybersecurity threats pose risks to the company's operations and could lead to significant legal and financial repercussions if data breaches occur [74]. - The company is making technology investments to improve or replace key information processes and systems, which are critical for managing business operations [78]. - Cybersecurity threats pose significant risks to the company's information systems, potentially leading to operational disruptions and reputational damage [76]. Financial Position and Strategy - The company relies on strong cash flows from operations to support growth plans, capital expenditures, and shareholder returns [86]. - The company must maintain sufficient liquidity to support its operations, capital investments, and stock repurchase programs [86]. - A hypothetical 100 basis point increase or decrease in prevailing market interest rates would not have a material negative impact on the company's financial position or results of operations [181]. Geographic Concentration and Risks - The company has a concentration of store locations in California, Texas, and Florida, which together account for almost 50% of its stores, exposing it to risks from natural disasters [88]. Growth Strategy - The growth strategy relies on expanding into new geographic markets, which may involve higher costs and operational inefficiencies [65]. Legal and Regulatory Risks - The company is subject to various legal and regulatory risks, including compliance with consumer product safety laws, which could result in product recalls and increased costs [89].

Operational Performance - As of December 31, 2025, the company has a total of 550 productive wells, with 365 net wells[83]. - In 2025, the company turned 33 gross development wells to sales, compared to 8 gross wells in 2024, indicating a significant increase in operational activity[86]. - The company has 10 gross development wells in progress as of December 31, 2025, with 7 net wells expected to come online in Q1 2026[87]. - The total developed acreage in the DJ Basin is 53,350 gross acres and 41,302 net acres, while undeveloped acreage totals 44,778 gross acres and 26,711 net acres[89]. - Approximately 21% of net undeveloped acreage (14,311 acres) may expire in 2026 if production is not established, with plans to extend certain leases[91]. - The company has no exploratory drilling activities or dry holes reported for the years ended December 31, 2025, and 2024[87]. - The company has 59 full-time employees as of December 31, 2025, and has not experienced any work stoppages, indicating stable employee relations[154]. Financial Performance - For the years ended December 31, 2025 and 2024, the company incurred a net loss attributable to Prairie Operating Co. common stockholders of $60.9 million and $40.9 million, respectively, with an accumulated deficit of $87.7 million and $119.8 million as of December 31, 2025 and 2024[223]. - The company has historically relied on cash from financing activities to fund substantially all of its cash requirements, indicating a dependency on external capital[223]. - The company may require significant additional capital to fund its growing operations, including planned drilling of oil and natural gas wells, and may not be able to obtain sufficient capital[224]. - The company’s ability to obtain external financing may be subject to uncertainties, including its future financial condition and results of operations[226]. - The company has outstanding Series D Preferred Stock convertible into 1,196,337 shares of Common Stock, and Series F Preferred Stock convertible into 21,468,687 shares of Common Stock[257]. - The Series F Preferred Stock was issued for approximately $148.3 million and is convertible into shares of Common Stock at a price of $5.00 per share[256]. - The company has outstanding warrants that provide the right to purchase an aggregate of 5,019,163 shares of Common Stock at $7.49 per share[258]. - For the year ended December 31, 2025, the company incurred a basic and diluted loss per common share of $1.35[263]. Regulatory Environment - Regulatory compliance is a significant factor affecting operations, with potential changes in laws and regulations that could impact costs and operational capabilities[99]. - The FTC can impose fines of approximately $1,510,803 per violation per day for market manipulation as of 2025, adjusted annually for inflation[106]. - FERC has the authority to assess civil penalties of up to $1,000,000 per day for violations of the NGA, with the maximum penalty increasing to $1,584,648 per violation per day in January 2025[111]. - The CFTC can seek civil penalties of up to approximately $1,487,712 as of 2025 for violations of anti-market manipulation sections of the CEA, adjusted annually for inflation[112]. - The federal Energy Policy Act of 2005 introduced anti-market manipulation provisions, enhancing FERC's enforcement authority[111]. - Changes in FERC or state policies may adversely affect the availability and reliability of transportation services on interstate and intrastate pipelines[107]. - The regulation of natural gas transportation and sales is primarily governed by the Natural Gas Act of 1938 and enforced by FERC[109]. - The Clean Water Act imposes strict controls on the discharge of pollutants into state waters, requiring permits for such discharges[123]. - The Oil Pollution Act of 1990 imposes joint and several liability on responsible parties for oil spill damages, affecting operational costs[125]. - State regulation of natural gas gathering facilities may increase, impacting operational compliance and costs[115]. - The classification of natural gas gathering facilities is subject to ongoing litigation, which may affect operational costs and regulatory compliance[114]. - The company is subject to increased regulatory scrutiny regarding air emissions, with new standards requiring routine leak monitoring and emissions controls for existing sources[128]. - The EPA's proposed rule to expand the Greenhouse Gas Reporting Program could raise compliance costs for the company, with new reporting obligations effective from January 1, 2025[131]. - The Inflation Reduction Act of 2022 introduced a methane emissions charge starting at $900 per metric ton in 2024, which could significantly impact operational costs[134]. - Colorado's Senate Bill 19-181 mandates a 16% royalty on oil production and a 13% royalty on gas production for force-pooled interests, affecting the company's financial obligations[144]. - The CECMC has implemented new regulations that could increase well costs and extend the time required to obtain drilling permits, creating uncertainty for future development plans[146]. - The company faces potential operational delays and increased costs due to stricter local government regulations on oil and natural gas facility siting[145]. - The EPA's recent actions regarding GHG emissions could lead to significant costs for compliance and operational adjustments[135]. - The company may incur additional costs if federal regulations on hydraulic fracturing are adopted, impacting exploration and production activities[139]. - The identification of new endangered species could impose restrictions on the company's operations, potentially affecting reserve development[141]. - The company is subject to ongoing legal challenges regarding climate-related disclosure rules, which could impact reporting requirements and associated costs[132]. - The company is subject to various environmental regulations that may increase operational costs and affect project timelines[160]. - The company’s operations are concentrated in the DJ Basin, which exposes it to geographic-specific risks[160]. - The regulatory burden on the oil and natural gas industry is increasing, which may lead to higher costs and reduced profitability[200]. - The company faces potential increased operating costs due to new climate-related disclosure regulations, which may also restrict access to capital[205]. - The United Nations' Paris Agreement aims for a 30% reduction in global methane emissions from 2020 levels by 2030, impacting fossil fuel funding[206]. - Litigation risks are rising as various entities allege that energy companies contribute to climate change, which could adversely affect the company's financial condition[207]. - Financial risks are increasing as institutional investors shift towards non-fossil fuel sectors, with over $130 trillion committed to net zero goals by GFANZ[208]. - The company’s operations may be affected by physical risks from climate change, including severe weather events that could damage assets and disrupt supply chains[209]. - Regulatory scrutiny on hydraulic fracturing is increasing, potentially leading to higher costs and operational delays due to new permitting and disclosure requirements[214]. - Access to water for operations may be restricted due to drought or new regulations, impacting planned exploration and production activities[215]. - The company may face increased costs and operational challenges related to the disposal of produced water due to regulatory changes and seismic activity concerns[216][217]. - Future legislation could eliminate certain federal income tax deductions for oil and natural gas exploration, adversely affecting financial performance[219]. - Changes in U.S. trade policy and tariffs may create volatility in commodity markets, impacting the company's operations and results[220]. Strategic Considerations - The company plans to develop and operate existing and future E&P assets, which will require substantial additional capital that may not be raised on acceptable terms[167]. - The company faces risks related to obtaining necessary permits for drilling, which can delay operations and affect financial performance[163]. - The company has entered into hedging arrangements to mitigate risks associated with fluctuations in oil and natural gas prices, but these may also lead to financial losses[162]. - The success of drilling operations is uncertain, with risks including the possibility of not encountering commercially productive reserves and unexpected drilling conditions[170]. - The company intends to pursue horizontal drilling in the DJ Basin, which is generally more complex and costly than vertical drilling, increasing operational risks[174]. - Future capital requirements will depend on various factors, including the ability to raise additional capital through equity or debt financing, which could dilute existing stockholders' ownership[168]. - The company relies on midstream infrastructure for marketing oil and natural gas production, and any inability to access such infrastructure could materially affect its business[185]. - Estimated reserves of oil, natural gas, and NGLs are based on assumptions that may prove inaccurate, affecting the present value of reserves[183]. - The company may incur material impairments of oil and natural gas properties if drilling results are less than anticipated or if capital constraints limit operations[175]. - The availability of transportation options for oil and natural gas production is subject to federal and state regulations, which can impact the company's operations[186]. - The company faces strong competition from major integrated oil and natural gas companies and numerous independent firms, which may have larger capital resources and operational capabilities[190]. - All exploration and production (E&P) assets are located in the DJ Basin, making the company vulnerable to regional risks such as natural disasters and regulatory changes[193]. - Recent leadership changes, including the resignation of the CEO and retirement of the President, may impact the company's strategic direction and operational effectiveness[230]. - The company may explore strategic acquisitions and joint ventures, which could disrupt ongoing business and may not result in profitable operations[238]. - The terms of the company's indebtedness may restrict its future business operations, including limitations on paying dividends and incurring additional debt[236]. - Future litigation or governmental proceedings could result in material adverse consequences, including substantial payments that may affect the company's liquidity[242]. - The company has experienced stock price volatility, with a low of $1.57 and a high of $9.50 per share during the 12 months ended December 31, 2025[263]. - The trading market for Common Stock may be influenced by analysts' coverage; a downgrade or lack of coverage could lead to a decline in stock price[271]. - The company has broad discretion to issue additional securities, which may result in substantial dilution to stockholders[270].

Product Development and Clinical Trials - Cyclerion is focusing on developing CYC-126 as a novel anesthetic-based therapy for treatment-resistant depression (TRD), which represents a significant clinical and commercial opportunity [26]. - CYC-126 combines propofol and dexmedetomidine, administered through a personalized delivery system, aiming to improve patient outcomes in a hospital setting [29]. - The company plans to initiate a Phase 2 proof-of-concept study for CYC-126 in Australia in the second half of 2026, with U.S. enrollment expected to start in the first half of 2027 [27]. - More than one-third of patients with medication-treated major depressive disorder (MDD) are estimated to meet criteria for TRD, representing approximately 2.8 to 3 million adults in the U.S. [30]. - The company has in-licensed a product candidate for treatment-resistant depression (TRD), but the development may never lead to marketable products [123]. - The completion or commencement of clinical studies may face delays due to regulatory holds or negative results from ongoing studies [149]. - Challenges in recruiting participants and obtaining necessary approvals can further delay clinical studies [150]. - The regulatory approval processes for product candidates are lengthy and unpredictable, with no approvals obtained for any product candidates to date [148]. - The company may face difficulties in enrolling participants in future clinical studies, potentially delaying product candidate progress [123]. - The NDA submission process includes extensive nonclinical and clinical trials, with a focus on safety and efficacy, and must comply with federal regulations [78]. - Clinical trials are conducted in three phases, with Phase 3 trials involving a larger participant group to demonstrate effectiveness and safety [83]. Financial Position and Funding - The company has incurred significant losses and has never generated revenue from product sales, anticipating continued losses for the foreseeable future [123]. - There is substantial doubt regarding the company's ability to continue as a going concern, necessitating additional funding in the near-term [123]. - The company plans to seek additional capital through equity or financing transactions to support the Phase 2 trials and general working capital [35]. - As of December 31, 2025, the company had approximately $3.2 million in unrestricted cash and cash equivalents, which management believes will not be sufficient to fund operations through mid-2026 [137]. - The company may need to raise additional funding in the near term, which may not be available on acceptable terms, potentially forcing it to curtail operations [137]. - The company has never generated revenue from product sales and may never achieve profitability [135]. - The company has a limited operating history with no products approved for commercial sale, which poses risks to its financial position [123]. Intellectual Property and Licensing - Cyclerion has entered into a license agreement with MIT, which could yield up to $4.4 million in milestone payments and tiered royalties based on future net sales of licensed products [27]. - A collaboration agreement with Medsteer SAS includes potential milestone payments of up to $3.7 million and annual royalties based on future net sales [27]. - The company has 22 issued U.S. patents and 12 pending U.S. patent applications related to its sGC programs, indicating a strong intellectual property position [56]. - The olinciguat patent portfolio includes 16 issued U.S. patents and five pending applications, with coverage extending to 2034 and beyond [65]. - The company entered into an Option to License Agreement for olinciguat, receiving an option fee of $150,000, but the agreement was terminated in October 2025 [53]. - The company is exploring potential licensing opportunities for olinciguat following the termination of the Option Agreement [53]. - The company has licensed a patent application from MIT for its TRD strategy and intends to apply for additional patents related to this product strategy [57]. - The company is subject to a non-compete agreement with Tisento until July 2028, restricting the development of competing products [48]. - The company’s patent term may be extended under the Drug Price Competition and Hatch-Waxman Act, allowing for additional protection for FDA-approved drugs [71]. - The pharmaceutical industry is characterized by extensive litigation regarding patents, which can be costly and time-consuming [188]. - If patents are invalidated or found unenforceable, the company's business and financial condition could be materially harmed [186]. - The company may face challenges regarding the inventorship or ownership of its patents, which could impact its intellectual property rights [191]. Regulatory Compliance and Risks - The FDA approval process for drugs requires substantial time and financial resources, with the potential for administrative or judicial sanctions for non-compliance [74]. - The company must comply with extensive FDA regulations post-approval, including recordkeeping and periodic reporting [96]. - The company is subject to U.S. federal and foreign anti-corruption laws, including the FCPA, which may impact its operations [102]. - Compliance with FDA regulations is critical, as failure to meet these standards could delay regulatory approval and commercialization of product candidates [170]. - The company faces risks related to the potential misappropriation of confidential information shared with third parties, which could adversely affect its competitive position [171]. - Compliance with healthcare regulations is critical, as violations could lead to substantial penalties, including civil and criminal penalties, which may harm financial results [214]. - The company may face claims regarding the wrongful use of trade secrets, which could result in litigation and distract management [203]. Market Competition and Challenges - The company faces competition from major pharmaceutical firms and specialized biotechs in the TRD market, which may impact its market position [108]. - The company faces significant competition from major pharmaceutical and biotechnology companies, which may have greater financial resources and expertise in research and development [220]. - Regulatory approval for product candidates is crucial; failure to obtain approvals before competitors could hinder market entry and financial performance [219]. - The competitive landscape includes potential litigation regarding intellectual property rights, which could limit demand for the company's product candidates [221]. - The potential market for the company's product candidates may be smaller than estimated, impacting revenue and profitability [205]. - The company lacks an established infrastructure for sales and marketing, which could hinder the commercialization of approved product candidates [206]. - Regulatory approval does not guarantee market acceptance, which is crucial for generating sufficient revenue [208]. - The reimbursement process for product candidates is time-consuming and costly, with uncertainty regarding coverage and adequate reimbursement levels [211]. - The company may not be able to provide sufficient data to gain acceptance for coverage and reimbursement, affecting commercialization efforts [212]. - Pricing negotiations for prescription drugs in the European Union can take considerable time and may be influenced by governmental controls, potentially harming business if reimbursement is limited [213]. - The Inflation Reduction Act of 2022 and other healthcare reforms may adversely affect revenue prospects and the ability to set fair prices for products [222]. - Future growth may depend on the ability to commercialize products outside the United States, which involves additional regulatory burdens and risks [223]. - Foreign sales could be impacted by governmental controls, political instability, trade restrictions, and changes in tariffs [224].

Revenue Performance - Total revenue for the three months ended February 28, 2026, was $247,799,000, representing a 4% increase compared to $238,015,000 for the same period in 2025[61]. - Software licenses revenue increased by 16% to $67,581,000 in Q1 2026, up from $58,445,000 in Q1 2025, accounting for 27% of total revenue[62]. - Maintenance revenue slightly increased by 1% to $100,339,000, while SaaS revenue grew by 2% to $70,461,000; professional services revenue decreased by 11% to $9,418,000[63]. - The company's Annualized Recurring Revenue (ARR) was $863.0 million as of February 28, 2026, representing a 2% increase year-over-year from $849.0 million as of February 28, 2025[84]. - The net retention rate has generally ranged between 99% and 100% for all periods presented, indicating strong customer retention and expansion[86]. Expenses - Cost of software licenses rose by 3% to $3,013,000, representing 4% of software licenses revenue, attributed to increased royalty costs[64]. - Product development expenses increased by 9% to $50,474,000, accounting for 20% of total revenue, primarily due to higher personnel-related costs[69]. - General and administrative expenses rose by 3% to $26,504,000, maintaining 11% of total revenue, driven by higher stock-based compensation[70]. - Cyber vulnerability response expenses increased by 84% to $1,358,000, representing 1% of total revenue, related to costs from the MOVEit Vulnerability[72]. - Acquisition-related expenses dropped by 67% to $814,000, reflecting lower costs associated with business combinations compared to $2,490,000 in the prior year[74]. Tax and Other Financial Metrics - Provision for income taxes surged by 217% to $7,479,000, with an effective tax rate of 25%, up from 18% in the previous year[76]. - Total other expense, net, decreased by 15% to $16,173,000, primarily due to reduced interest expenses[75]. Cash Flow and Liquidity - Cash and cash equivalents increased by $18.4 million from the end of fiscal year 2025, totaling $113.2 million as of February 28, 2026, driven by cash inflows from operations of $98.6 million[87]. - Net cash flows provided by operating activities for the three months ended February 28, 2026, were $98.6 million, compared to $68.9 million for the same period in the previous year[89]. - The company plans to utilize worldwide cash based on the needs of the parent entity, with $69.0 million of cash and cash equivalents held by foreign subsidiaries[88]. - The company expects existing cash balances and funds generated from operations to be sufficient to finance operations and meet foreseeable cash requirements for at least the next twelve months[98]. - The company is continuously evaluating additional financing options to support general corporate purposes or repay outstanding indebtedness[99]. Shareholder Returns - The company repurchased $20.4 million of common stock in the first three months of fiscal year 2026, down from $30.1 million in the same period of the prior year[93]. - The Board of Directors approved the suspension of the quarterly dividend to redirect capital towards debt repayment and future M&A activities[95]. Accounts Receivable - As of February 28, 2026, gross accounts receivable decreased by $50.8 million, with days sales outstanding (DSO) improving to 52 days from 73 days in the previous fiscal quarter[91].